Survival after GO without IL-11 and after GO with IL-11.

(A) Probability of survival following treatment with GO without IL-11 or GO with IL-11. Kaplan-Meier estimates of the proportion of patients remaining alive from the start of treatment (P = .20 on log-rank test). Sixteen of the 26 patients given GO without IL-11 and 13 of the 25 given GO with IL-11 have died. Median censoring times were 14 weeks for GO without IL-11 and 17 for GO with IL-11. Noting the relatively small number of patients with MDS treated, survival depended more on whether patients received GO with or without IL-11 than on whether they had AML or MDS (data not shown). (B) Probability of survival following treatment with GO without IL-11 or GO with IL-11 in patients with a normal karyotype. Kaplan-Meier estimates of the proportion of patients remaining alive from start of treatment (P = .24 on log-rank test). Four of the 9 patients given GO without IL-11 and 2 of the 11 given GO with IL-11 have died. Median censoring time was 14 weeks for both GO without IL-11 and GO with IL-11.